NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT
Post# of 175
(Total Views: 179)
Posted On: 12/02/2022 4:38:01 PM
NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Recognized for ‘Unique Approach to Heart Attack Diagnosis’
HeartBeam (NASDAQ: BEAT) was recently named the winner of the annual Cardiovascular Innovations (“CVI”) 2022 Information Summit and Shark Tank Competition, an annual conference that focuses on innovative health solutions for cardiology clinicians. Awards presented at the conference recognize state-of-the-art cardiac technologies. “The company, which has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has made a mark for itself in the cardiac care field by building an intellectual-property portfolio focused on enabling 12-lead ECG diagnostics outside of a medical setting. Most recently, HeartBeam announced that it was issued a new patent, which enables generation of a synthesized 12-lead ESG by the HeartBeam AIMIGo(TM) credit card-sized device, by the United States Patent and Trademark Office (‘USPTO’)… The HeartBeam AIMI-platform technology is anticipated to assist health care professionals in identifying patients who present with chest pain to facilitate rapid detection of a heart attack and determine an appropriate treatment regimen,” a recent article reads. “We are proud that HeartBeam has been recognized for our unique approach to heart attack diagnosis,” HeartBeam CEO and Founder Branislav Vajdic, PhD., is quoted as saying. “Our goal is to provide a solution that offers both health care professionals and patients peace of mind regarding their diagnosis and treatment plan.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT) was recently named the winner of the annual Cardiovascular Innovations (“CVI”) 2022 Information Summit and Shark Tank Competition, an annual conference that focuses on innovative health solutions for cardiology clinicians. Awards presented at the conference recognize state-of-the-art cardiac technologies. “The company, which has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has made a mark for itself in the cardiac care field by building an intellectual-property portfolio focused on enabling 12-lead ECG diagnostics outside of a medical setting. Most recently, HeartBeam announced that it was issued a new patent, which enables generation of a synthesized 12-lead ESG by the HeartBeam AIMIGo(TM) credit card-sized device, by the United States Patent and Trademark Office (‘USPTO’)… The HeartBeam AIMI-platform technology is anticipated to assist health care professionals in identifying patients who present with chest pain to facilitate rapid detection of a heart attack and determine an appropriate treatment regimen,” a recent article reads. “We are proud that HeartBeam has been recognized for our unique approach to heart attack diagnosis,” HeartBeam CEO and Founder Branislav Vajdic, PhD., is quoted as saying. “Our goal is to provide a solution that offers both health care professionals and patients peace of mind regarding their diagnosis and treatment plan.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)